The Expression Pattern of TCR Vγ I∼III Subfamilies in GVHD Patients After Allogenic Hematopoietic Stem Cell Transplantation.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2219-2219
Author(s):  
Xiuli Wu ◽  
Can Liu ◽  
Yu Zhang ◽  
Zhiping Fan ◽  
Qifa Liu

Abstract Abstract 2219 Poster Board II-196 Objective The γΔ+ T cells can act as a vast functional setting of immune defense against pathogenic invaders in chronic inflammatory reactions, as well as in modulating systemic and organ-specific autoimmune diseases. Recently, it was reported that γΔ+ T cells might play an important role in regulation of graft versus host disease (GVHD), mediation of graft versus leukemia effect, anti-virus infection, anti-cancer effect and so on. But the frequency of T cell receptor (TCR) Vγ repertoire and the expression patterns of TCR Vγ subfamilies in GVHD remain unknown. To further study on the characteristics of TCR Vγ subfamilies in GVHD, we investigated the frequency of TCR Vγ repertoire and the expression of TCR Vγ I∼III subfamilies genes in the patients with GVHD after allogenic hematopoietic stem cell transplantation (allo-HSCT). Methods The expression and cloanlity analysis of TCR Vγ repertoire was detected in peripheral blood mononuclear cells (PBMNCs) from 25 patients with GVHD by RT-PCR and genescan technique. The TCR Vγ I∼III genes expression levels of PBMNCs from patients with GVHD were detected using the real-time fluorescence quantitative polymerase chain reaction with SYBR Green I technique and relative quantification method. Twelve healthy individuals served as normal controls. Results The RT-PCR results showed that in GVHD patients, the expression frequency of TCR Vγ I was 88.0% (22/25), TCR Vγ II was 72.0% (18/25), and TCR Vγ III was 96.0% (24/25). All of the three TCR Vγ subfamilies could be detected in PBMNCs from the normal controls. TCR Vγ repertoires with polyclonal pattern were identified in normal controls. However, the skew expression pattern of TCR Vγ repertoire could be detected in patients with GVHD even more than 4 year after allo-HSCT. Oligoclonal or monoclonal expanded T cells were identified in TCR Vγ I∼III subfamilies in GVHD patients. The expression level of TCR Vγ II gene in the PBMNCs from patients with GVHD was significant lower than the normal controls (P<0.05). The pattern of TCR Vγ gene expression levels in GVHD was TCR Vγ I> TCR Vγ III> TCR Vγ II, however, the expression pattern in normal controls was TCR Vγ II> TCR Vγ I > TCR Vγ III. Conclusions The expression patterns of TCR Vγ I∼III subfamilies were changed in GVHD. The low expression of TCR Vγ II subfamily might be related with the pathogenesis of GVHD. Disclosures: No relevant conflicts of interest to declare.

2020 ◽  
Vol 29 ◽  
pp. 096368972096698
Author(s):  
Wanyi Ye ◽  
Xueting Kong ◽  
Wenbin Zhang ◽  
Zheng Weng ◽  
Xiuli Wu

The αβ T-cell-depleted hematopoietic stem cell transplantation (HSCT) leads to lower relapse and better outcome, and may correlate strongly with expansion of donor-derived γδ T cells. γδ T cells play an important role in immune reconstitution and can exert a graft-versus-leukemia effect after HSCT. This review showed the recent literature on immune functions of γδ T cells after HSCT. The discrepancies between studies of γδ T cells in graft-versus-host disease may cause by its heterogeneous and various distinct subsets. And reconstitution of γδ T cells may play a potential immunoregulatory role in the infections after HSCT.


2021 ◽  
Vol 20 (2) ◽  
pp. 143-147
Author(s):  
O. O. Molostova ◽  
L. N. Shelikhova ◽  
D. E. Pershin ◽  
A. M. Popov ◽  
M. E. Dubrovina ◽  
...  

Presently, there is no consensus on the best treatment for relapsed B-cell acute lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients with extramedullary lesions. There are certain anti-tumor drugs that can be used in case of relapse after allo-HSCT, however, prospective randomized studies directly comparing different chemotherapy and immunotherapy approaches are generally lacking. Retrospective studies exploring therapy for relapsed disease are difficult to compare due to the inhomogeneity of patient populations and the diversity of treatment approaches. In such situations, the treatment choice is influenced by the characteristics of the tumor population, particularly, its immunophenotype, available drugs, and the experience of a healthcare facility and physicians. This clinical case report describes the process of treating a patient with B-lymphoblastic lymphoma and shows the possibility of using donor CD19-specific CAR-T cells as a treatment for isolated CNS relapse after allo-HSCT. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.


2020 ◽  
Vol 11 ◽  
Author(s):  
Sabrina Basso ◽  
Francesca Compagno ◽  
Paola Zelini ◽  
Giovanna Giorgiani ◽  
Stella Boghen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document